Keyphrases
Reduced Toxicity
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Intravenous Busulfan
100%
Myeloablation
100%
Busulfan
50%
Graft-versus-host Disease (GvHD)
50%
Engraftment
33%
Hematological Malignancies
33%
Disease-free Survival
33%
Toxicity Profile
33%
Transplantation Conditioning
33%
Allogeneic Transplantation
33%
Drug Delivery
16%
High Dose
16%
Plasma Parameters
16%
Common Component
16%
Mortality Risk
16%
Treatment-related
16%
Favorable Outcome
16%
Acute Lymphoblastic Leukemia
16%
Myeloid Leukemia
16%
Curative Treatment
16%
Leukemia
16%
Unrelated Donor
16%
HLA-matched Donor
16%
Living Donor
16%
Clinical Practice
16%
Overall Survival
16%
Disease Status
16%
Advanced Disease
16%
Allograft
16%
Tight Control
16%
Myeloablative Conditioning
16%
Cytoreductive Surgery
16%
Relapsed or Refractory
16%
Matched Unrelated
16%
Veno-occlusive Disease of the Liver
16%
Organ Toxicity
16%
Underdosing
16%
Mismatched Related Donor
16%
Myeloid Disorders
16%
Multi-variant Model
16%
Immunology and Microbiology
Conditioning
100%
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Myeloid
50%
Engraftment
50%
Allotransplantation
50%
Disease Free Survival
50%
Acute Graft Versus Host Disease
50%
Blood Level
25%
Transplant Procedure
25%
Graft-Versus-Host Disease
25%
Drug Megadose
25%
Survival Rate
25%
Allotransplantation
25%
Overall Survival
25%
Medicine and Dentistry
Conditioning
100%
Allogeneic Hematopoietic Stem Cell Transplantation
100%
Busulfan
100%
Disease
44%
Hematologic Malignancy
22%
Engraftment
22%
Disease Free Survival
22%
Transplantation Conditioning
22%
Allotransplantation
22%
Acute Graft Versus Host Disease
22%
Survival Rate
11%
Myeloid Leukemia
11%
Drug Megadose
11%
Leukemia
11%
Transplantation
11%
Acute Lymphoblastic Leukemia
11%
Allograft
11%
Overall Survival
11%
Bioavailability
11%
Vein Occlusion
11%
Graft Versus Host Reaction
11%
Nonmyeloablative Conditioning
11%
Organ Toxicity
11%
Pharmacology, Toxicology and Pharmaceutical Science
Busulfan
100%
Disease
44%
Disease Free Survival
22%
Hematologic Malignancy
22%
Acute Graft Versus Host Disease
22%
Leukemia
11%
Acute Lymphoblastic Leukemia
11%
Bioavailability
11%
Survival Rate
11%
Overall Survival
11%
Vein Occlusion
11%
Graft Versus Host Reaction
11%
Organ Toxicity
11%
Myeloid Leukemia
11%